BRAF mutation in papillary thyroid carcinoma

Yoram Cohen, Mingzhao Xing, Elizabeth Mambo, Zhongmin Gou, Guogun Wu, Barry Trink, Uziel Beller, William H. Westra, Paul W. Ladenson, David Sidransky

Research output: Contribution to journalArticlepeer-review

Abstract

The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 24 (69%) of the 35 papillary thyroid carcinomas examined, we found a missense thymine (T)→adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer.

Original languageEnglish (US)
Pages (from-to)625-627
Number of pages3
JournalJournal of the National Cancer Institute
Volume95
Issue number8
DOIs
StatePublished - Apr 16 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'BRAF mutation in papillary thyroid carcinoma'. Together they form a unique fingerprint.

Cite this